Abstract #4732

The feasibility of ADC in optimizing chemotherapy for 5-FU-resistant gastric cancer with mouse model: when should replace 5-FU with paclitaxel?

Jia Sun¹, Lai-yun Zhang¹, Lei Yang¹, Zhu-lin Li¹, Qing-lei Shi², and Tao Jiang¹

¹Beijing Chaoyang Hospital of Capital Medical Universit, Beijing, China, ²Siemens Healthcare,MR Scientific Marketing,Beijing China, Beijing, China

In this study, we verified the feasibility of apparent diffusion coefficient (ADC) values in predicting chemotherapy response and optimizing chemotherapy regimen for gastric cancer that is resistant 5-FU with mouse model. We found that based on the early changes of ADC to replace 5-FU with paclitaxel in advance can effectively reduce tumor burden which means it may be possible to use ADC values as a reliable bio-marker in predicting chemotherapy response and optimizing chemotherapy regimen for gastric cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.